- 询价
- BIO-RAD
- MCA1642FT
- 2025年10月17日
- F
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Human lymphocytes
- 亚型：
IgG2b
- 形态：
Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- 克隆性：
Monoclonal Antibody
- 标记物：
FITC
- 适应物种：
Human
- 保质期：
自发货之日起 12 个月
- 目录编号：
YTH34.5
- 供应商：
伯乐生命医学产品（上海）有限公司
- 应用范围：
F
- 浓度：
IgG concentration 0.1 mg/ml
- 抗体名：
CD52 antibody | YTH34.5
- 规格：
25 µg/0.1 mg
| 规格： | 25 µg | 产品价格： | 询价 |
|---|---|---|---|
| 规格： | 0.1 mg | 产品价格： | 询价 |
Rat anti Human CD52 antibody, clone YTH34.5 recognizes the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link (Xia et al. 1991).
The apparent molecular mass of the native antigen on SDS-PAGE is 25-29 kDa, considerably reduced following N-glycanase treatment (Rowan et al. 1998).
CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.
Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Dearden et al. 2002; Pettitt et al. 2012).
The apparent molecular mass of the native antigen on SDS-PAGE is 25-29 kDa, considerably reduced following N-glycanase treatment (Rowan et al. 1998).
CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.
Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Dearden et al. 2002; Pettitt et al. 2012).
储存信息
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
应用
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | ✓ | Neat |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10μl of the suggested working dilution to label 106 cells or 100μl whole blood
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
References for CD52 antibody
- Klangsinsirikul, P. et al. (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
Blood. 99: 2586-91. - Ratzinger, G. et al. (2003) Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Blood. 101: 1422-9. - Zand, M.S. et al. (2005) A renewable source of donor cells for repetitive monitoring of T- and B-cell alloreactivity.
Am J Transplant. 5: 76-86. - Westermann, J. et al. (2005) CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
Int J Hematol. 82 (3): 248-50. - Gopcsa, L. et al. (2005) Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells.
Eur J Haematol. 75: 346-51. - Rodig SJ et al. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Clin Cancer Res. 12 (23): 7174-9. - Golay, J. et al. (2006) The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Haematologica. 91: 322-30. - Miles, R.R. et al. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
Br J Haematol. 138: 506-12.
Further Reading
- Salisbury JR et al. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
J Clin Pathol. 47 (4): 313-7. - Hale G et al. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Blood. 92 (12): 4581-90.
技术资料暂无技术资料 索取技术资料
文献支持
Rat anti Human CD52:FITC，clone YTH34.5
询价
